AB Science webcast – Microtubule Destabilizer Agents (MDA) platform
16/03/2023 – Presentation of the AB Science Microtubule Destabilizer Agents platform webcast
AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET
15/03/2023 – AB Science will host a live webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/2 with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
13/03/2023 – AB Science today announces a case report from the initial stage of its Phase I/II study (AB18001) evaluating AB8939, a microtubule destabilizer, in patients with refractory and relapsed acute myeloid leukemia (AML)
Publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer’s Research & Therapy
28/02/2023 – AB Science today announced publication of results from its positive pivotal phase 3 trial of masitinib in mild-to-moderate Alzheimer’s disease (AD) in Alzheimer’s Research & Therapy
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank
31/01/2023 – AB Science announced today that it has received payment of €6.0 million as the second tranche of a €15 million loan from the European Investment Bank (EIB)
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
29/12/2022 – AB Science announced today that its Phase III clinical trial (AB20009) in progressive forms of multiple sclerosis has been approved by the US Food and Drug Administration (FDA)
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
27/12/2022 – AB Science today announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS)
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
22/12/2022 – AB Science announced today that it has received payment of €6.0 million as the first tranche of a €15 million loan from the European Investment Bank (EIB)
AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
13/12/2022 – AB Science announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease
21/11/2022 – AB Science today announced that it has received an Investigational New Drug (IND) approval letter from the FDA to initiate Phase III study (AB21004) in patients with mild to moderate Alzheimer’s disease